Switch theme
Sign up to access all valuation multiples
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
2005
14.9K+
LTM Revenue $13.3B
LTM EBITDA $2.7B
$39.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Daiichi Sankyo has a last 12-month revenue (LTM) of $13.3B and a last 12-month EBITDA of $2.7B.
In the most recent fiscal year, Daiichi Sankyo achieved revenue of $13.0B and an EBITDA of $3.0B.
Daiichi Sankyo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Daiichi Sankyo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.3B | XXX | $13.0B | XXX | XXX | XXX |
| Gross Profit | $10.4B | XXX | $10.2B | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $2.7B | XXX | $3.0B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $2.2B | XXX | $2.3B | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $2.1B | XXX | $2.0B | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Daiichi Sankyo's stock price is JPY 3365 (or $23).
Daiichi Sankyo has current market cap of JPY 6.27T (or $43.4B), and EV of JPY 5.65T (or $39.1B).
See Daiichi Sankyo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.1B | $43.4B | XXX | XXX | XXX | XXX | $1.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Daiichi Sankyo has market cap of $43.4B and EV of $39.1B.
Daiichi Sankyo's trades at 3.1x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Daiichi Sankyo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daiichi Sankyo has a P/E ratio of 21.1x.
See valuation multiples for Daiichi Sankyo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43.4B | XXX | $43.4B | XXX | XXX | XXX |
| EV (current) | $39.1B | XXX | $39.1B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 17.4x | XXX | 18.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.1x | XXX | 23.0x | XXX | XXX | XXX |
| EV/FCF | -198.9x | XXX | 303.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaiichi Sankyo's last 12 month revenue growth is 10%
Daiichi Sankyo's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Daiichi Sankyo's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Daiichi Sankyo's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Daiichi Sankyo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daiichi Sankyo acquired XXX companies to date.
Last acquisition by Daiichi Sankyo was XXXXXXXX, XXXXX XXXXX XXXXXX . Daiichi Sankyo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Daiichi Sankyo founded? | Daiichi Sankyo was founded in 2005. |
| Where is Daiichi Sankyo headquartered? | Daiichi Sankyo is headquartered in Japan. |
| How many employees does Daiichi Sankyo have? | As of today, Daiichi Sankyo has 14.9K+ employees. |
| Who is the CEO of Daiichi Sankyo? | Daiichi Sankyo's CEO is Mr. Sunao Manabe. |
| Is Daiichi Sankyo publicy listed? | Yes, Daiichi Sankyo is a public company listed on TKS. |
| What is the stock symbol of Daiichi Sankyo? | Daiichi Sankyo trades under 4568 ticker. |
| When did Daiichi Sankyo go public? | Daiichi Sankyo went public in 2005. |
| Who are competitors of Daiichi Sankyo? | Similar companies to Daiichi Sankyo include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Daiichi Sankyo? | Daiichi Sankyo's current market cap is $43.4B |
| What is the current revenue of Daiichi Sankyo? | Daiichi Sankyo's last 12 months revenue is $13.3B. |
| What is the current revenue growth of Daiichi Sankyo? | Daiichi Sankyo revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Daiichi Sankyo? | Current revenue multiple of Daiichi Sankyo is 2.9x. |
| Is Daiichi Sankyo profitable? | Yes, Daiichi Sankyo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Daiichi Sankyo? | Daiichi Sankyo's last 12 months EBITDA is $2.7B. |
| What is Daiichi Sankyo's EBITDA margin? | Daiichi Sankyo's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Daiichi Sankyo? | Current EBITDA multiple of Daiichi Sankyo is 14.2x. |
| What is the current FCF of Daiichi Sankyo? | Daiichi Sankyo's last 12 months FCF is -$196M. |
| What is Daiichi Sankyo's FCF margin? | Daiichi Sankyo's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Daiichi Sankyo? | Current FCF multiple of Daiichi Sankyo is -198.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
